Patent details

Basic Information

Publication number:

EP2575881

PCT Application Number:

PCT/EP/2011/058777

Type:

European Patent Granted for LU

Legal Status:

Lapsed

Application number:

EP117285940

PCT Publication Number:

WO/2011/147984

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

ANTI-CD160 SPECIFIC ANTIBODIES FOR THE TREATMENT OF EYE DISORDERS BASED ON NEOANGIOGENESIS

French Title of Invention:

ANTICORPS SPÉCIFIQUES ANTI-CD160 POUR UN TRAITEMENT DE TROUBLES OCULAIRES BASÉES SUR LA NÉOANGIOGENÈSE

German Title of Invention:

SPEZIFISCHE ANTI-CD160-ANTIKÖRPER ZUR BEHANDLUNG VON AUGENERKRANKUNGEN AUF GRUNDLAGE VON NEOANGIOGENESE

SPC Number:

Dates

Filing date:

27/05/2021

Grant date:

14/09/2016

EP Publication Date:

14/09/2016

PCT Publication Date:

01/12/2011

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

10/04/2013

EP B1 Publication Date:

14/09/2016

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

27/05/2017

Expiration date:

21/12/2021

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

28/06/2018

 

 

Name:

Elsalys Biotech

Address:

321 avenue Jean Jaures, 69007 Lyon, France (FR)

From:

02/12/2016

 

 

Name:

INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM)

Address:

101, RUE DE TOLBIAC, 75013, PARIS, France (FR)

Inventor

1

Name:

BENSUSSAN Armand

Address:

France (FR)

2

Name:

LE BOUTEILLER Philippe

Address:

France (FR)

Priority

Priority Number:

349271 P

Priority Date:

28/05/2010

Priority Country:

United States (US)

Classification

Main IPC Class:

A61K 39/00;

Annual Fees

Annual Fee Due Date:

Annual Fee Number:

Expected Payer:

Last Annual Fee Payment Date:

Last Annual Fee Paid Number:

Payer:

Filing date	Document type	Number of pages